This study is for people with advanced pancreatic ductal adenocarcinoma (PDAC), a type of cancer. Researchers want to create models, or plans, to predict how long patients will live, how long before cancer gets worse, and how well the treatment works using patient images, tissue samples, and genetic information.

**Key Points:**

• Participants must have a confirmed PDAC diagnosis and be at least 18 years old.
• Individuals should not have received certain treatments or vaccines recently, and must not have other active severe illnesses.
• The study involves assessments and tests before and during the first-line maintenance treatment but compensations or exact visit details are not specified.

In eligibility terms, patients can't have had major surgeries recently, certain autoimmune diseases, or infections like HIV. They also cannot be allergic to specific chemotherapy drugs unless using different ones. The study requires participants to understand and agree to its purpose, which is called providing informed consent.